Effects of Suloctidil on Platelet Survival Time Following Cardiac Valve Replacement

Abstract

SummaryPlatelet functions and blood clotting parameters were examined in 23 patients with a shortened platelet survival time after cardiac valve replacement.Treatment was given at random: for a first group antivitamins K with suloctidil and for the second group antivitamin K alone.Six weeks of treatment with antivitamin K alone did not induce any significant change in the platelet survival time, platelet retention or platelet factor 4 in plasma.In contrast, the shortened platelet survival time increased significantly after 6 weeks of treatment with suloctidil. Moreover the platelet retention and the amount of platelet factor 4 in plasma were significantly reduced, indicating that normalization of platelet survival is the result of decreased destruction, presumably at the level of the prosthetic surface. The clinical benefits expected from these results remain to be validated by a longer follow up period.

Studies of Suloctidil in Experimental Thrombosis in Baboons

“…Previous reports show that suloctidil has marked antispasmodic effects (4), inhibits some in vitro measurements of platelet function and is an effective antithrombotic agent in a number of experimental models and some clinical conditions (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15). These effects have been attributed to membrane changes (25,26), cellular metabolic alterations (26,27) or competitive inhibition of stimuli (3).…”

Drugs Effect on Platelet Survival Time: Comparison of Two Pyrimido-Pyrimidine Derivatives in Patients with Aortic or Mitral Replacement

“…It is well know n th at controlled trials have less frequent positive results than poorly designed trials (28). T he only study whose design is relevant com pared suloctidil to nothing (5). In addition, our study differs from previous reports by oth er characteristics which might be set forth to explain negative outcom e. O ur patients w ere investigated for PST m eas urem ents no longer than 3 m onths after operation.…”

“…T hree reported series did n ot provide evidence for shortened PST (17,24,26). O ne is equivocal (5).…”

Antiplatelet Drugs in the Management of Patients with Thrombotic Disorders

“…Suloctidil, a peripheral vasodilator, without a well-defined antithrombotic mechanism 152 normalizes platelet survival in patients with prosthetic heart valves. 153 ' 154 In a well-designed clinical trial, suloctidil has shown no benefit in reducing stroke and death in patients with a recent thromboembolic stroke. 23 The results in trials of patients with venous thrombosis are controversial.…”